|
Post by nuklerfizzacist on May 8, 2015 11:52:09 GMT -5
I've looked back at all jpg's posts. Not very pragmatic for a highly educated person - discounts mnkd's never ending fall back position of "must be patent" that we heard today and for the last eight years, discounts the unsubstantiated "potential" that we heard today and for the last eight years, the list goes on and on, but never a moment of reflection on how bad this management may be. A reason for jpg to continually support this egregiously incompetent ceo and cfo is that he is actually a mankind plant. Well, that (plant talk) makes no sense whatsoever and you likely just got this thread locked. The management is not bad. ..they did create an amazing paradigm changing product. Their only knock: they are just trying to continue operating /communicating as if they are still trying to establish a product. ..this is their only negative in my opinion. They just need to evolve...they likely will after today.
|
|
|
Post by jpg on May 8, 2015 11:52:22 GMT -5
I've looked back at all jpg's posts. Not very pragmatic for a highly educated person - discounts mnkd's never ending fall back position of "must be patent" that we heard today and for the last eight years, discounts the unsubstantiated "potential" that we heard today and for the last eight years, the list goes on and on, but never a moment of reflection on how bad this management may be. A reason for jpg to continually support this egregiously incompetent ceo and cfo is that he is actually a mankind plant. Mannkind plant! I like that... Doesn't matter if you are serious or not but that is actually funny. Who new Mannkind cared that much about ProBoards? it's simple really: sales take time. Paradigm shifts take time. Al Mann and Mannkind has so far done more than 99.9% of companies for diabetics. Extraordinary medications eventually catch on. I simply think management is honest and doing what needs to be done. Type 1s will be the anchor market and as studies role in type 2 diabetics will join in. At a minimum this is a financially viable niche market insulin for type 1s alone. Done right this will be a very popular drug.
|
|
|
Post by esstan2001 on May 8, 2015 11:55:51 GMT -5
Today prompts me to write this open letter to Mannkind Management:
You all owe a tremendous debt of gratitude to Al Mann for his genius, foresight, perseverance, and financial commitment in driving Afrezza through the FDA hoops to approval... now it is your turn to repay him with an effective, nimble execution that gets Afrezza into the hands of T1/T2 patients in a manner that validates how correct Al Mann was regarding this being a tremendous blockbuster- possibly the greatest selling drug of all time. And it all needs to be done in a manner that makes it obvious to Al very soon; that is the least you owe to him for the opportunities he had provided to you all.
|
|
|
Post by nuklerfizzacist on May 8, 2015 11:58:00 GMT -5
I've looked back at all jpg's posts. Not very pragmatic for a highly educated person - discounts mnkd's never ending fall back position of "must be patent" that we heard today and for the last eight years, discounts the unsubstantiated "potential" that we heard today and for the last eight years, the list goes on and on, but never a moment of reflection on how bad this management may be. A reason for jpg to continually support this egregiously incompetent ceo and cfo is that he is actually a mankind plant. Mannkind plant! I like that... Doesn't matter if you are serious or not but that is actually funny. Who new Mannkind cared that much about ProBoards? it's simple really: sales take time. Paradigm shifts take time. Al Mann and Mannkind has so far done more than 99.9% of companies for diabetics. Extraordinary medications eventually catch on. I simply think management is honest and doing what needs to be done. Type 1s will be the anchor market and as studies role in type 2 diabetics will join in. At a minimum this is a financially viable niche market insulin for type 1s alone. Done right this will be a very popular drug. I'm so relieved i used the word paradigm in my post before your post came through. ..otherwise we might be accused of being best ferns. Best ferns...plant...whew...tough audience. .no worries...I'm here all week. Try the veal .
|
|
|
Post by savzak on May 8, 2015 11:59:38 GMT -5
Today prompts me to write this open letter to Mannkind Management: ... now it is your turn to repay him with an effective, nimble execution that gets Afrezza into the hands of T1/T2 patients Getting Afrezza into the hands of diabetics is almost entirely in the hands of SNY.
|
|
|
Post by gomnkd on May 8, 2015 12:00:04 GMT -5
My thoughts:
1) First lets give credit to where it is due. MNKD mgmt is responsible for production, inventory etc. So far we've not heard of any quality issues, plant shut down or products returned as defective etc. This they have it in their control and have done a great job.
2) Sales and mktg are outside of their control, they might have given inputs to SNY. SNY has to work with the current system to get it moving. I don't know what prevented them from doing a lease of spiro with payment due when it is used. Issue is Afrezza is life and death for MNKD and just a rounding error for Sanofi. Even for AL Mann this is the first mass market product he has developed. I'm glad Hakan mentioned about Afrezza being a pull product, not a push one. DTC will validate this and I agree with him. The French wont be taking advice from a start-up outfit.
3) Matt's non-dilution comment without giving specifics is borderline criminal.
4) MNKD still has no sense of urgency about controlling cash burn outside partnership. Hiring CMO is boneheaded move when nothing was accomplished regarding TS platform for last several years.
Only thing going good for us is current set of patients: Sam Finta, Amy T and others. We'll bottom out (don't know at what price) prior to DTC. Forget the 10 bagger. I'll happy to exit major portion at post-approval highs sometime in next 3 years. There still lot of downside left. This board appears only 50% bearish and trending down, we need that sentiment to bottom out first.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on May 8, 2015 12:06:57 GMT -5
I've looked back at all jpg's posts. Not very pragmatic for a highly educated person - discounts mnkd's never ending fall back position of "must be patent" that we heard today and for the last eight years, discounts the unsubstantiated "potential" that we heard today and for the last eight years, the list goes on and on, but never a moment of reflection on how bad this management may be. A reason for jpg to continually support this egregiously incompetent ceo and cfo is that he is actually a mankind plant. good job on your first post.
|
|
|
Post by esstan2001 on May 8, 2015 12:07:47 GMT -5
Getting Afrezza into the hands of diabetics is almost entirely in the hands of SNY. Mostly true however there are certainly things Mannkind can do around the edges to lubricate this a bit. They need to get tighter with Sanofi on this joint operations thing; they can respectfully exert pressure where appropriate as I am sure Sanofi sees the position they are in as a result of where the roll out is (I am not saying this is anything near disaster; but Mannkind needs to demonstrate they are on top of things and in command as much as can be made visible) The next opportunity comes with the annual meeting. I hope to see some signs of improvement- in the messaging, and how they are perceived regarding effective operations (esp in light of the fact that other Technosphere opportunities are now pushed further out than they led us to believe) The importance of this fades as sales ramp up. So, they can worry less about looking like they've kicked back on their laurels IF things are operating.
|
|
|
Post by dreamboatcruise on May 8, 2015 12:16:04 GMT -5
I sort of listened to the call while multitasking... so missed some things.
I think something was said about ongoing trials. Can someone who paid close attention summarize what was said? I need to go back and listen this weekend, but just being inpatient.
|
|
|
Post by kball on May 8, 2015 12:23:01 GMT -5
Today prompts me to write this open letter to Mannkind Management: You all owe a tremendous debt of gratitude to Al Mann for his genius, foresight, perseverance, and financial commitment in driving Afrezza through the FDA hoops to approval... now it is your turn to repay him with an effective, nimble execution that gets Afrezza into the hands of T1/T2 patients in a manner that validates how correct Al Mann was regarding this being a tremendous blockbuster- possibly the greatest selling drug of all time. And it all needs to be done in a manner that makes it obvious to Al very soon; that is the least you owe to him for the opportunities he had provided to you all. Better sent to Sanofi Management imo. A lot of todays conf call seemed to stop just short of saying Sanofi has screwed up the launch thus far
|
|
|
Post by seanismorris on May 8, 2015 12:27:31 GMT -5
My impression was management thought (thinks) the existing trials will be sufficient to get Afrezza approved. But, I didn't hear Europe (in its entirety) specifically. Maybe Japan? I'm not sure which country generally follows the FDA's lead. We'll have to wait for the call transcripts...this was one of many things that wasn't clear.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on May 8, 2015 12:33:58 GMT -5
In addition to being woefully unprepared, Hakan and Matt seemed nervous to me almost as if they were prohibited from speaking. Something is up, perhaps something good is brewing or significant storm clouds on the horizon. Symphony NRx counts today from my perspective fair at best as I would think peer to peer discussion would drive NRx in a positive manner.
I really wish when they were getting questions about things they were not allowed to divulge that they would have just said so in a direct, concise and diplomatic manner. The analysts may not have liked it but the overall tone and respect for leadership would have been better.
I am still trying to figure out what the Spirometry excuse is a cover for. To give docs billing codes for a spiro test is easy enough and SNY could buy units in bulk and distribute in a way so as not to violate kickback laws and proactively having a plan to go from the start to me seems obvious as the light of day.
The prior authorization issue as I understand it is not as big of a deal today as years gone by because there are software programs that reside on the pharmacies computers that automate the entire process.
Like I said, something is up and I just wish I knew what it was.
Question for the group: Did Al lay into Matt and Hakan after the call.
|
|
|
Post by compound26 on May 8, 2015 12:36:01 GMT -5
Mike at Tudiabetes.org commented today that "I've spoken to Sam on the phone and am interested in seeing the interview as well. I still use Afrezza for all meal and correction boluses. My Omnipod is just a basal pump at this point."
Guys, let's calm down. It just takes time for Afrezza to take the market. What Sanofi and Mannkind are selling are not iphones that fans are lining up outside Apple Store or Bestbuy to pick them up. Afrezza will catch on, one patient by one patient, slowly, but steadily.
All in all, Afrezza was only launched for about 90 days. Per this piece of news published on 6 May 2015, (http://www.wdbj7.com/news/local/new-inhaled-insulin-takes-the-place-of-mealtime-injections/32845044#.VUvhbm2EQiI.twitter ), "at the busy Endocrinology Associates office in Roanoke, the inhaler became available to patients less than a month ago."
So we are only in the very early stages of rollout. But see what the doctors and patients are saying:
"Patients like it," said Endocrinologist Dr. D. James Bailey. "I think it's going to be very popular."
"This allows people to take their mealtime insulin, the fast acting insulin without having to take an injection," said Dr. Bailey. "They can take it with just a short puff on the delivery system."
"All they have to do is remove the little tip (on the inhaler) and then inhale and it goes right in so it doesn't have a propellant," Dr. Bailey said.
Dr. Bailey's patients are now just beginning to use Afrezza. So far the feedback is positive.
"They like not having to take injections and in fact they're starting to tell their friends who take injections at meals about this," said Dr. Bailey. "So we've had a lot of inquires."
All in all, it just takes time.
|
|
|
Post by kball on May 8, 2015 12:37:07 GMT -5
My impression was management thought (thinks) the existing trials will be sufficient to get Afrezza approved. But, I didn't hear Europe (in its entirety) specifically. Maybe Japan? I'm not sure which country generally follows the FDA's lead. We'll have to wait for the call transcripts...this was one of many things that wasn't clear. My interpretation was that JAPAN wouldn't fall under existing trials but that europe would
|
|
|
Post by esstan2001 on May 8, 2015 12:40:07 GMT -5
Today prompts me to write this open letter to Mannkind Management: You all owe a tremendous debt of gratitude to Al Mann for his genius, foresight, perseverance, and financial commitment in driving Afrezza through the FDA hoops to approval... now it is your turn to repay him with an effective, nimble execution that gets Afrezza into the hands of T1/T2 patients in a manner that validates how correct Al Mann was regarding this being a tremendous blockbuster- possibly the greatest selling drug of all time. And it all needs to be done in a manner that makes it obvious to Al very soon; that is the least you owe to him for the opportunities he had provided to you all. Better sent to Sanofi Management imo. A lot of todays conf call seemed to stop just short of saying Sanofi has screwed up the launch thus far Well... to yours and Savzak's point, yes- you do have a point here. Sanofi bears almost all the responsibility for where we are. (BTW, I do believe this has always been characterized as a controlled launch by both partners... they certainly could have messaged their surprise at the slow uptake better given this). I am hoping that Mannkind management implores Sanofi to do more, or give permission to say more about any corrective actions / plans... whatever they can get in time for the annual meeting, to stem any potential further share price declines (the only other foreseeable material thing we have to gauge with is script counts).
|
|